Constellation Pharmaceuticals to Host Conference Call to Discuss Second Quarter 2020 Results
Constellation Pharmaceuticals will host a conference call on August 5, 2020, at 8:00 AM EDT to discuss its Q2 2020 results and updates on clinical programs. Interested parties can access the live webcast through the Investor Relations section of their website. The company focuses on developing novel therapeutics for cancer, particularly utilizing epigenetic modifications. Their lead candidates include the BET inhibitor CPI-0610 for myelofibrosis and the EZH2 inhibitor CPI-0209 for other cancers.
- None.
- None.
CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on August 5, 2020, to discuss its second quarter 2020 results and progress in its clinical programs. The event will be webcast live and can be accessed on the Investor Relations section of Constellation’s website at http://ir.constellationpharma.com/events-and-presentations/events. To participate in the live question-and-answer session, please dial (877) 473-2077 (domestic) or (661) 378-9662 (international) and refer to conference ID 4372778.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as its EZH2 inhibitor CPI-0209 for the treatment of other cancers. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.
Contacts
Kia Khaleghpour
Vice President, Investor Relations and Communications
Constellation Pharmaceuticals
+1 617-844-6859
kia.khaleghpour@constellationpharma.com
Ronald Aldridge
Senior Director, Investor Relations
Constellation Pharmaceuticals
+1 617-714-0539
ron.aldridge@constellationpharma.com
Lauren Arnold
Media Relations
MacDougall Biomedical Communications
+1 781-235-3060
larnold@macbiocom.com
FAQ
What is the date of Constellation Pharmaceuticals' Q2 2020 conference call?
What time will the Constellation Pharmaceuticals call take place?
How can I access the Constellation Pharmaceuticals conference call?
What are the lead drugs being discussed by Constellation Pharmaceuticals?
What is the purpose of Constellation Pharmaceuticals' conference call?
